Table 1 Patient and disease specific characteristics.

From: Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure

Year of transplantation

1989–2019

1989–2000

2001–2010

2011–2019

Total n (%)

220 (100%)

36 (16.4%)

108 (49.1%)

76 (34.5%)

Age (years), median (range)

55 (20–75)

42 (25–64)

57 (22–75)

57 (20–74)

Female, n (%)

92 (41.8%)

14 (38.9%)

44 (40.7%)

34 (44.7%)

Molecular risk group

 Favorable, n (%)

2 (0.9%)

0 (0%)

0 (0%)

2 (2.6%)

 Intermediate, n (%)

60 (27.3%)

10 (27.8%)

30 (27.8%)

21 (27.6%)

 Adverse, n (%)

77 (35%)

8 (22.2%)

33 (30.6%)

36 (47.4%)

 Missing molecular risk, n (%)

81 (36.8%)

18 (50%)

45 (41.7%)

17 (22.4%)

Blast count (BM) before conditioning therapy, median % (range)

36% (0–95%)

50% (8–90%)

40% (0–95%)

28% (0–90%)

 Present, n (%)

184 (83.6%)

13 (63.9%)

94 (87%)

67 (88.2%)

 Aplasia, n (%)

18 (8.2%)

1 (2.8%)

9 (8.3%)

8 (10.5%)

 n.a., n (%)

18 (8.2%)

12 (33.3%)

5 (4.6%)

1 (1.3%)

Circulationg blast count (PB) before conditioning therapy, median % (range)

5% (0–98%)

5.5% (0–73%)

6% (0–98%)

2.5% (0–98%)

 Present, n (%)

114 (51.8%)

9 (25%)

65 (60.2%)

40 (52.6%)

 Absent, n (%)

91 (41.4%)

13 (36.1%)

42 (38.9%)

36 (47.4%)

 n.a., n (%)

15 (6.8%)

14 (38.9%)

1 (0.9%)

0 (0%)

ECOG score

 0–1, n (%)

173 (78.6%)

9 (25%)

95 (88%)

69 (90.8%)

 2–4, n (%)

22 (10%)

2 (5.6%)

13 (12%)

7 (9.2%)

 n.a., n (%)

25 (11.4 %)

25 (69.4 %)

0 (0 %)

0 (0%)

HCT-CI, median (range)

3 (0–12)

n.a.

3 (0–7)

3 (0–12)

 0–3, n (%)

56 (25.5%)

n.a.

21 (19.4%)

35 (46.1%)

 ≥4, n (%)

34 (15.5%)

n.a.

15 (13.9%)

19 (25%)

 n.a., n (%)

130 (59.1%)

36 (100%)

72 (66.7%)

22 (28.9%)

AML type

 De novo AML, n (%)

135 (61.4%)

20 (55.6%)

63 (58.3%)

52 (68.4%)

 sAML, n (%)

65 (29.5%)

12 (33.3%)

36 (33.3%)

17 (22.4%)

 MDS, n (%)

55 (84.6 %)

12 (100%)

30 83.3%)

13 (76.5%)

 MPN, n (%)

7 (10.8%)

0 (0%)

3 (8.3 %)

4 (23.5%)

 MDS/MPN Overlap, n (%)

3 (4.6 %)

0 (0%)

3 (8.3%)

0 (0%)

 t-AML, n (%)

20 (9.1%)

4 (11.1%)

9 (8.3%)

7 (9.2%)

Time from primary disease to tAML (years), median (range)

6.5 (0.5–20)

5.6 (0.5–11.2)

3 (1.4–18.9)

10.6 (2.0–20)

Number of treatment lines before HCT, median (range)

2 (1–6)

2 (1–6)

2 (1–5)

2 (1–5)

 n.a., n (%)

14 (38.9%)

13 (36.1%)

1 (0.9%)

0 (0%)

Time from diagnosis to HCT (months), median (range)

3.48 (0.48–14.52)

3.96 (1.08–12.96)

3.72 (0.48–14.52)

2.88 (0.48–13.08)

  1. Shown are patient and disease specific characteristics for the entire cohort (n = 220, column B) as well as for the three sub-cohorts according to the year of transplantation (column C: 1989–2000, n = 36; column D: 2001–2010, n = 108; column E: 2011–2019, n = 76).
  2. BM bone marrow, n.a. not assessed, PB peripheral blood, ECOG Eastern Cooperative Oncology Group Score, HCT-CI Hematopoietic Cell Transplantation-specific Comorbidity Index, AML acute myeloid leukemia, sAML secondary acute myeloid leukemia, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasm syndrome, tAML treatment-related acute myeloid leukemia, HCT hematopoietic cell transplantation.
Back to article page